Frontotemporal dementias: Clinical features and management

Seminars in Clinical Neuropsychiatry

Volumn 8, Issue 1, 2003, Pages 58-70

  Chow, Tiffany W ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; AMFEBUTAMONE; BROMOCRIPTINE; BUSPIRONE; CARBIDOPA PLUS LEVODOPA; GUANFACINE; HALOPERIDOL; IDAZOXAN; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VALPROIC ACID; PSYCHOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; ANXIETY DISORDER; APHASIA; BEHAVIOR DISORDER; BRADYKINESIA; CLINICAL FEATURE; CONFERENCE PAPER; CONSCIOUSNESS DISORDER; CONSTIPATION; DISEASE EXACERBATION; DROWSINESS; FEMALE; FRONTOTEMPORAL DEMENTIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; LIVEDO RETICULARIS; MALE; MOOD DISORDER; MUSCLE RIGIDITY; NERVE DEGENERATION; NIGHTMARE; PALLIATIVE THERAPY; PARKINSONISM; PSYCHOSIS; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; VIVID DREAM; XEROSTOMIA; ARTICLE; BRAIN CORTEX; DEMENTIA; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; NERVE CELL NETWORK; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PSYCHOLOGICAL ASPECT;

AGED; ALZHEIMER DISEASE; CEREBRAL CORTEX; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; GUANFACINE; HUMANS; NERVE NET; NEUROPSYCHOLOGICAL TESTS; PSYCHOTROPIC DRUGS;

EID: 0037258638     PISSN: 10843612     EISSN: None     Source Type: Journal    
DOI: 10.1053/scnp.2003.50000     Document Type: Conference Paper

References (58)

1. Brun A, Englund B, Gustafson L, et al: Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester groups. J Neurology, Neurosurgery Psychiatry 57:416-418, 1994
2. McKhann GM, Albert MS, Grossman M, et al: Clinical and pathological diagnosis of frontotemporal dementia. Arch Neurology 58:1803-1809, 2001
3. Neary D, Snowden JS, Gustafson L, et al: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546-1554, 1998
4. Brun A: Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatrics 6: 193-208, 1987
5. The Lund and Manchester Groups: Clinical and neuropathological criteria for frontotemporal dementia. J Neurology, Neurosurgery, Psychiatry 57:416-418, 1994
6. Chow TW, Hodges J, Dawson K, et al: Gender and age at onset in frontotemporal dementia syndromes. Neurology 58:A379-A380, 2002 (suppl 3)
7. Lendon CL, Lynch T, Norton J, et al: Hereditary dysphasic disinhibition dementia. A frontotemporal dementia linked to 17q21-22. Neurology 50:1546-1555, 1998
8. Stevens M, van Duijn CM, Kamphorst W, et al: Familial aggregation in frontotemporal dementia. Neurology 50: 1541-1545, 1998
9. Mendez MF, Chow T, Ringman J, et al: Pedophilia and temporal lobe disturbances. J Neuropsychiatry Clin Neurosci 12:71-76, 2000
10. Miller BL, Darby A, Benson DF, et al: Aggressive, socially disruptive and antisocial behavior associated with fronto-temporal dementia. Br J Psychiatry 170: 150-155, 1997
11. Miller BL, Darby AL, Swartz JR, et al: Dietary changes, compulsions and sexual behavior in frontotemporal degeneration. Dementia 6:195-199, 1995
12. Mendez MF, Perryman KM, Miller BL, et al: Compulsive behaviors as presenting symptoms of frontotemporal dementia. J Geriatric Psychiatry Neurology 10:154-157, 1997
13. Levy M, Miller BL, Cummings JL, et al: Alzheimer's disease and frontotemporal dementias: behavioral distinctions. Arch Neurology 53:687-690, 1996
14. Mendez MF, Selwood A, Mastri AR, et al: Pick's disease versus Alzheimer's disease: comparison of clinical characteristics. Neurology 43:289-292, 1993
15. Edwards-Lee T, Miller BL, Benson DF, et al: The temporal variant of frontotemporal dementia. Brain 120(Pt. 6):1027-1040, 1997
16. Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neuroscience 9:357-381, 1986
17. Cummings JL: Frontal-subcortical circuits and human behavior. Arch Neurology 50:873-880, 1993
18. Mega MS, Cummings JL: Frontal-subcortical circuits and neuropsychiatric disorders [see comments]. J Neuropsychiatry Clin Neurosciences 6:358-370, 1994
19. Chow TW, Cummings JL: Frontal-subcortical circuits, in Miller BL, Cummings JL (eds): The Human Frontal Lobes: Functions and Disorders. New York, Guilford Press, 1999, pp 1-26
20. Miller BL, Chang L, Nena I, et al: Progressive right frontotemporal degeneration: Clinical neuropsychological, and SPECT characteristics. Dementia 4:204-213, 1993
21. Miller BL, Boone K, Cumminas JL, et al: Functional correlates of musical and visual ability in frontotemporal dementia. Br J Psychiatry 176:458-463, 2000
22. Miller BL, Cummings J, Mishkin F, et al: Emergence of artistic talent in frontotemporal dementia. Neurology 51:978-982, 1998
23. Miller BL, Ponton M, Benson DF, et al: Enhanced artistic creativity with temporal lobe degeneration. Lancet 348:1744-1745, 1996
24. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al: Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 58:198-208, 2002
25. Chan D, Fox NC, Scahill RI, et al: Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurology 49:421-423, 2001
26. Galton CJ, Gomez-Anson B, Antoun N, et al: Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. J Neurology Neurosurgery Psychiatry 70:165-173, 2001
27. Small GW, Ercoli LM, Silverman DH, et al: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease [see comments]. Proc National Acad Sci USA 97:6037-6042, 2000
28. Miller BL, Cummings JL, Villanueva-Meyer J, et al: Frontal lobe degeneration: clinical, neuropsychological and SPECT characteristics. Neurology 41:1374-1382, 1991
29. Neary D, Snowden JS, Shields RA, et al: Single photon emission tomography using 99mTc-HM-PAO in the investigation of dementia. J Neurol Neurosurg Psychiatry 50:1101-1109, 1987
30. Wilhelmsen KC, Lynch T, Pavlou E, et al: Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 55:1159-1165, 1994
31. Yamaoka LH, Welsh-Bohmer KA, Hulette CM, et al: Linkage of frontotemporal dementia to chromosome 17: clinical and neuropathological characterization of phenotype. Am J Human Genetics 59:1306-1312, 1996
32. Lynch T, Sano M, Marder KS, et al: Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex [see comments]. Neurology 44:1878-1884, 1994
33. Bird TD, Wijsman EM, Nochlin D, et al: Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology 48:949-954, 1997
34. Basun H, Almkvist O, Axelman K, et al: Clinical characteristics of a chromosome 17-linked rapidly progressive familial frontotemporal dementia. Arch Neurol 54: 539-544, 1997
35. Urrutia L, Read M, Swartz R, et al: Differentiation of Alzheimer's disease, frontotemporal dementia and parkinsonian-dementias. Facts and Research in Gerontology. Alzheimer's Disease 7-16, 1996
36. Arnsten AF, Goldman-Rakic PS: Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230:1273-1276, 1985
37. Cai JX, Ma YY, Xu L, et al: Reserpine impairs spatial working memory performance in monkeys: reversal by the alpha 2-adrenergic agonist clonidine. Brain Research 614:191-196, 1993
38. Arnsten AF, Cai JX, Goldman-Rakic PS: The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neuroscience 8:4287-4298, 1988
39. Franowicz JS, Arnsten AF: The alpha-2a noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys. Psychopharmacology 136:8-14, 1998
40. Rama P, Linnankoski I, Tanila H, et al: Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacology, Biochem Behavior 55:415-422, 1996
41. Jakala P, Sirvio J, Riekkinen M, et al: Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans. Neuropsychopharmacology 20:119-130, 1999
42. Jakala P, Riekkinen M, Sirvio J, et al: Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 20:460-470, 1999
43. Chappell PB, Riddle MA, Scahill L, et al: Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolescent Psychiatry 34:1140-1146, 1995
44. Hunt RD, Arnsten AF, Asbell MD: An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolescent Psychiatry 34:50-54, 1995
45. Chow TW: Open label trial of guanfacine in frontotemporal dementia. Am J Alzheimer's Dis (in press)
46. Sahakian BJ, Coull JJ, Hodges JR: Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type. J Neurology, Neurosurgery Psychiatry 57:120-121, 1994
47. Albert ML, Bachman DL, Morgan A, et al: Pharmacotherapy for aphasia. Neurology 38:877-879, 1988
48. Tanaka Y, Albert ML, Hujita K, et al: Dopamine agonist improves speech output in nonfluent aphasia. Neurology 54:A102, 2000 (suppl 3)
49. Yang Y, Schmitt HP: Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathologica 101:256-270, 2001
50. Sparks DL, Markesbery WR: Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurology 48:796-799, 1991
51. Sjogren M, Minthon L, Passant U, et al: Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging 19:379-384, 1998
52. Swartz R, Miller BL, Lesser IM, et al: Behavioral phenomenology in Alzheimer's disease, frontotemporal dementia, and late-life depression: a retrospective analysis. J Geriatric Psychiatry Neurology 10:67-74, 1997
53. Chouinard G, Saxena B, Belanger MC, et al: A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affective Disorders 54:39-48, 1999
54. Magnuson TM, Roccaforte WH, Wengel SP, et al: Medication-induced dystonias in nine patients with dementia. J Neuropsychiatry Clin Neurosci 12:219-225, 2000
55. Lebert F, Pasquier F: Trazodone in the treatment of behaviour in frontotemporal dementia [letter to the editor]. Human Psychopharmacology 14:279-281, 1999
56. Mitsuyama Y: Presenile dementia with motor neuron disease. Dementia 4:137-142, 1993
57. Hooten WM, Lyketsos CG: Frontotemporal dementia: a clinicopathological review of four postmortem studies. J Neuropsychiatry Clin Neurosci 8:10-19, 1996
58. Gregory CA, Lough S: Practical issues in the management of early onset dementia, in Hodges JR (ed): Early Onset Dementia: a multidisciplinary approach. Oxford, Oxford University Press, 2001, pp 443-459